DelveInsight’s “Alopecia Areata Pipeline Insight, 2024,” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Alopecia Areata Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Alopecia Areata Overview
Alopecia areata is a type of non-scarring hair loss that primarily affects hair follicles and nails, with rare involvement of the retinal pigment epithelium. It typically presents as round patches of hair loss. The hair follicle normally has a relative immune privilege, characterized by the suppression of surface molecules needed to present autoantigens to CD8+ T lymphocytes (i.e., MHC class I) and the creation of an inhibitory local signaling environment. The breakdown of this immune privilege is considered a significant factor in the development of AA.
Alopecia Areata Pathophysiology
Alopecia areata is a disorder of the hair follicle cycle, where inflammatory cells attack the hair follicle matrix epithelium undergoing early cortical differentiation (anagen hair follicles). This attack prematurely induces the follicles into the catagen phase. Despite this, hair follicle stem cells remain intact, allowing the hair follicle to regenerate and continue its cycle. The follicles re-enter the anagen phase but do not progress beyond the anagen III/IV phase.
The immune privilege of the hair follicle collapses in alopecia areata, possibly due to proinflammatory signals (e.g., IFN-gamma, substance P) that upregulate MHC class Ia in the hair-follicle epithelium, exposing previously hidden follicle-associated autoantigens to preexisting autoreactive CD8+ T cells. Since only anagen hair follicles are attacked, these autoantigens may be generated and presented only during anagen. The precise trigger for alopecia areata is unknown, but it has been linked to factors such as emotional or physical stress, vaccines, viral infections, and drugs.
Alopecia Areata Treatment Options
Many therapeutic modalities have been used to treat alopecia areata, each with variable efficacy and safety profiles. Unfortunately, none of these treatments is curative or preventive. Additionally, many of these therapeutic agents have not been subjected to randomized, controlled trials, and, except for topical immunotherapy, there are few published studies on long-term outcomes. Common treatments include:
1. Topical Corticosteroids: Often the first line of treatment, especially for mild cases.
2. Intralesional Corticosteroids: Injected directly into the patches of hair loss.
3. Topical Immunotherapy: Involves applying substances like diphencyprone (DPCP) to induce an allergic reaction, which can stimulate hair growth.
4. Systemic Corticosteroids: Used for more severe cases but have significant side effects.
5. Minoxidil: A topical treatment that can promote hair growth.
6. JAK Inhibitors: Emerging treatments that target specific pathways involved in the immune response.
7. Phototherapy: Using ultraviolet light to stimulate hair growth.
Despite these treatments, long-term remission is rare, and continuous management is often required. Research into the underlying mechanisms and potential new treatments is ongoing, aiming to improve outcomes for those affected by this condition.
Alopecia Areata Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for the treatment of Alopecia Areata and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alopecia Areata market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Ongoing Clinical & Commercial Activities will Affect the Alopecia Areata Therapeutic Segment @ https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight
Alopecia Areata Emerging Drugs Profiles
Alopecia Areata Emerging Drugs
Deuruxolitinib: Concert Pharmaceuticals
Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.
EQ101: Equillium
EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.
MAX 40070: Maxinovel Pharmaceuticals
MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.
Alopecia Areata Therapeutics Landscape
There are approx. 20+ key companies developing therapies for Alopecia Areata. Currently, Pfizer is leading the therapeutics market with its Alopecia Areata drug candidates in the most advanced stage of clinical development.
Key Companies in the Alopecia Areata Therapeutics Market Include: Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma Company Limited, and others.
Alopecia Areata Emerging and Marketed Drugs Covered in the Report Include:
-
ARQ 255: Arcutis Biotherapeutics
-
CTP-543: Concert Pharmaceutical
-
Deuruxolitinib: Concert Pharmaceuticals
-
HCW 9302:HCW Biologics
-
LH-8: Legacy Healthcare
-
Ritlecitinib: Pfizer
-
SHR0302: Reistone Biopharma Company
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/alopecia-areata-pipeline-insight
Table of Contents
1. Report Introduction
2. Executive Summary
3. Alopecia Areata Current Treatment Patterns
4. Alopecia Areata – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Alopecia Areata Late Stage Products (Phase-III)
7. Alopecia Areata Mid-Stage Products (Phase-II)
8. Alopecia Areata Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alopecia Areata Discontinued Products
13. Alopecia Areata Product Profiles
14. Key Companies in the Alopecia Areata Market
15. Key Products in the Alopecia Areata Therapeutics Segment
16. Dormant and Discontinued Products
17. Alopecia Areata Unmet Needs
18. Alopecia Areata Future Perspectives
19. Alopecia Areata Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/